FIELD: medicine, endocrinology.
SUBSTANCE: invention elates to a method for treatment of diabetes mellitus type 2, method for declining the glucose content in patient blood and method for reducing resistance to insulin, diminishing the hemoglobin A1c content, enhancing the insulin level after eating, and reducing the amplitude change content ("mobility") of glucose in diabetic patients. Method involves administration of metformin to patient in the low dose (160-750 mg) in combination with the second anti-diabetic agent chosen from the group including glucose oxidase inhibitor, glucagons-like peptide-1 (GLP-1), insulin, α/β-double agonist of PRAP other than thiazolidinedione, meglitimide and inhibitor aP2 wherein the second anti-diabetic agent is administrated as a daily dose in interval between the initial daily dose comprising 20-60% of the initial daily dose of this anti-diabetic agent used in usual medicinal practice in therapy of the first order in treatment of diabetes mellitus up to the daily supporting dose comprising 40-60% of the daily supporting dose of this anti-diabetic agent used in usual medicinal practice as therapy of the first order in treatment of diabetes mellitus. Invention provides the effectiveness in treatment of diabetes mellitus that is equivalent practically to effectiveness of treatment by using combination of metformin and other indicated anti-diabetic agent used in doses prescribing in usual medicinal practice but with significantly less adverse effects.
EFFECT: improved method for treatment of diabetes mellitus.
7 cl, 10 dwg, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DIABETES TREATMENT | 2000 |
|
RU2275915C2 |
APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
METHODS OF DIACEREIN APPLICATION IN ADDITIONAL TREATMENT OF DIABETES | 2011 |
|
RU2563988C2 |
METHOD OF IMPROVEMENT OF LIVER FUNCTION | 2013 |
|
RU2653478C2 |
METHOD FOR TREATING METABOLISM DISORDERS MAINLY DIABETES CASES AND DISEASES OR STATES RELATED TO DIABETES | 2000 |
|
RU2280447C2 |
LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2670106C2 |
LIXISENATIDE AS ADD-ON THERAPY TO BASAL INSULIN IN TYPE 2 DIABETES | 2012 |
|
RU2606154C2 |
PHARMACEUTICAL COMBINATION CONTAINING SGLT2 INHIBITOR | 2008 |
|
RU2489151C2 |
COMBINATIONS AND COMPOSITIONS CONTAINING FATTY ACIDS AND AMINO ACIDS, THEIR APPLICATION FOR PREVENTION AND DELAY OF PROGRESSING OR TREATMENT OF DIABETES AND DIABETES ASSOCIATED DISEASES AND CONDITIONS, METHOD OF WEIGHT REDUCTION IN MAMMAL, KIT | 2004 |
|
RU2356247C2 |
Authors
Dates
2006-05-20—Published
2000-10-13—Filed